Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1452W HIGH $13.28
Volume
1.28 M
Value Traded
195.13 K
Short % Float
2.8%
Days to Cover
1.0
-40.07%Week
-87.32%1 Month
-93.1%3 Month
-93.65%6 Month
-99.27%5 Year
-99.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
829.68 K
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
-883.98 K
Total Shares
5.03 M
Float Shares
4.16 M
Insiders
17.36%
Institutions
3.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
LNAI Catalyst Timeline
Dated clinical, regulatory and corporate events for Lunai Bioworks Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lunai Bioworks Inc.
98Total events
6Upcoming
27Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Stock ListingCorporate
Board approved voluntary withdrawal of common stock from Nasdaq listing under Rule 12d2-2(c)
▼Stock ListingCorporate
Nasdaq staff determination to delist LNAI common stock for failure to meet $2.5M stockholders' equity rule
▲Partnership / LicenseCorporate
Lunai enters exclusive worldwide license and collaboration agreement with Tanaist for Parkinson's cellular phenotyping
Parkinson's diseasesource ↗
▲Preclinical PoCPreclinical
BioSymetrics case study demonstrates structure-based AChE inhibition screening with 5.1-fold enrichment using Tox21 data
chemical-safety and biosecurity (AChE inhibition prediction)source ↗
▲Partnership / LicenseCorporate
Lunai Bioworks and BrainStorm Therapeutics execute Master Collaboration Agreement
Parkinson's diseasesource ↗
▲Partnership / LicenseCorporate
Lunai's August 2026 collaboration with BrainStorm Therapeutics
Parkinson's diseasesource ↗
▲Partnership / LicenseCorporate
Established Pathfinder Consortium with Harvard, Brigham and Women's Hospital, University of Utah, Purdue, University of Colorado
▲Partnership / LicenseCorporate
Lunai Bioworks and BrainStorm Therapeutics launch AI discovery collaboration for Parkinson's and rare epilepsy
neurological diseasessource ↗
◆Quarterly UpdateCorporate
Special Meeting of Stockholders postponed from May 4 to May 8, 2026
▼Equity OfferingCorporate
Completed $20 million preferred equity issuance to acquire CNS delivery and neurotherapeutic IP
▲Partnership / LicenseCorporate
Acquired intellectual property assets from two counterparties for CNS delivery technologies
◆IP Litigation RulingIP / Competition
Initiated legal action in U.S. District Court for District of Delaware against unidentified parties for naked short selling
▲Partnership / LicenseCorporate
BioSymetrics enters revenue-generating defense collaboration for AI-enabled chemical threat assessment
chemical threat assessmentsource ↗
▲Partnership / LicenseCorporate
BioSymetrics multi-year, revenue-generating commercial defense collaboration announced
neuroactive and neurotoxic compound screening (chemical defense)source ↗
▲Platform ValidationPreclinical
Multi-year revenue-generating commercial defense collaboration combining predictive MoA analysis with in vivo zebrafish phenotypic screening
chemical defense and biosecurity (neuroactive/neurotoxic compound classification)source ↗
◆AcquisitionCorporate
Acquisition of BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group
CNS Alzheimer'ssource ↗
▲Partnership / LicenseCorporate
Acquisition of BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group
Alzheimer's diseasesource ↗
▲Preclinical PoCPreclinical
Completed key commercial milestone under NIH STTR initiative: generated high-resolution behavioral signatures of ethanol exposure and withdrawal
Alcohol Use Disordersource ↗
▲Trial InitiationTrial
Initiated new commercial drug discovery program targeting Alcohol Use Disorder
Alcohol Use Disordersource ↗
◆Product LaunchPost-Market
Planned test launch of decision support platform for medical oncologists
cancersource ↗
▼Equity OfferingCorporate
$10 million equity committed at $1.4726 per share with 10% warrant coverage
▲Partnership / LicenseCorporate
Renovaro and Amsterdam UMC sign MoU to establish joint company for personalized cancer immunotherapy
cancersource ↗
●Trial InitiationTrial
Phase 1/2 clinical trials of leading candidate for pancreatic cancer and solid tumors expected to begin
pancreatic cancer and other solid tumorssource ↗
◆Quarterly UpdateCorporate
Proxy statement filed for shareholder meeting on combination with GEDi Cube
◆Product LaunchPost-Market
Commercial launch of AI-based early cancer detection products
cancer detectionsource ↗
●IND SubmissionIND
IND submission expected in Q1 2024 for several solid tumor types
solid tumorssource ↗
◆Trial InitiationTrial
Clinical trials potentially starting soon after IND submission in early 2024
solid tumorssource ↗
◆IND SubmissionDC11IND
IND application filing for RENB-DC11 to initiate clinical trials
cancersource ↗
▲Pre IND MeetingFDA Meeting
FDA review of Pre-IND submission for Cancer Platform
solid tumors (pancreatic cancer, triple-negative breast cancer, oral cancers, mesothelioma)source ↗
◆Pre IND MeetingFDA Meeting
Pre-IND submission to US FDA imminent
pancreatic cancer and other solid tumorssource ↗
▼Equity OfferingCorporate
Raised approximately $2.5 million through private placement of restricted shares as of March 31, 2023
▲Oral PresentationPresentation
Proof-of-concept data presented at 8th Annual Innate Killer Summit
pancreatic cancersource ↗
◆Oral PresentationPresentation
Dr. Jewett presented key results at a scientific conference last week (late March 2023)
pancreatic cancersource ↗
▲Preclinical PoCDC11Preclinical
Preclinical validation of RENB-DC11 in pancreatic cancer humanized mice showing tumor regression
pancreatic cancersource ↗
●Trial InitiationTrial
Human studies enrollment start for inhaled Influenza treatment
Influenzasource ↗
◆Preclinical PoCPreclinical
Pivotal animal study for cell therapy candidate for HIV in monkeys
HIVsource ↗
Past FDA Catalysts and PDUFA Decisions
How LNAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LNAI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| William Anderson Wittekind10% Owner | Sell | -1,114 840,319 held | $1.30 | 07/29/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in LNAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LNAI for Q2 2026. | ||||
Ownership Trends
LNAI Short Interest
Shares sold short, counted twice a month.
2.8%
Short % of Float
of tradable shares sold short
116.5K
Shares Sold Short
-21.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
126.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LNAI ranks across every disease it competes in
Competitive Position is a premium feature
See how LNAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLNAI News
About Lunai Bioworks Inc.
HeadquartersCENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
BIOPHARMAWATCH ELITE
Trade the next LNAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime